FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Solid Tumor
Unknown Primary
18 Years and older, Male and Female
LOXO-FG3-22001 (primary)
NCI-2023-00367
022-502755-59-00
2022-502755-59-00
J4G-OX-JZVA
Summary
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435 by itself or when it is combined with other standard medicines
that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the
urinary system and other solid tumor cancers that have a change in a particular gene
(known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and
possibly longer if the disease does not get worse.
Objectives
This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered
advanced solid tumor malignancy including metastatic urothelial cancer (UC). The study
will be conducted in 2 phases: Phase 1a dose escalation (Cohort A1) and dose optimization
(Cohort A2) and Phase 1b dose expansion. Phase 1a will assess safety, tolerability, and
pharmacokinetics of LOXO-435 to determine the optimal dose for further expansion.
Phase 1b will include 6 dose expansion cohorts to evaluate the efficacy and safety of
LOXO-435 as monotherapy or in combinations with pembrolizumab with or without enfortumab
vedotin.
Eligibility
- Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable
- Cohort A1: Presence of an alteration in FGFR3 or its ligands
- Cohort A2, B2, B3, and B5: Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration
- Cohorts B1 and B4: Histological diagnosis of urothelial cancer that is locally advanced or metastatic
- Cohort C1: Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration
- Measurability of disease:
- Cohort A1 and B3: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)
- Cohorts A2, B1, B2, B4, B5, and C1: Measurable disease required as defined by RECIST v1.1
- Have adequate tumor tissue sample available. Participants with inadequate tissue sample availability may still be considered for enrollment upon review
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for Cohorts A1, A2, B3, and B5
- Less than or equal to 2 for Cohorts B1, B2, B4, and C1
- Prior Systemic Therapy Criteria:
- Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.
- Cohort A2, B2, B3 participants must have received at least one prior regimen, and cohorts B1 and B4 participants at least 2 prior regimens, in the locally advanced or metastatic setting
- There is no restriction on number of prior therapies
- Cohort B5: Participants have not received prior systemic therapy for locally advanced or metastatic UC
- FGFR inhibitor specific requirements:
- Cohort A1/A2/B3: Prior FGFR inhibitor treatment is permitted but not required
- Cohort B1/B4: Participants must have been previously treated with erdafitinib
- Cohort B2, B5, and C1: Participants must be FGFR inhibitor naïve
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.